GSA Capital Partners LLP Grows Stake in Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL)

Key Points

• GSA Capital Partners LLP increased its stake in Zentalis Pharmaceuticals by 275.9% in Q1, acquiring a total of 541,975 shares valued at approximately $862,000.
• Several analysts have rated Zentalis Pharmaceuticals with a consensus rating of "Moderate Buy", projecting a target price of $8.37, with HC Wainwright setting a more optimistic target of $10.00.
• Zentalis Pharmaceuticals reported earnings of ($0.67) per share for the last quarter, meeting analysts' expectations, with predictions for an annual EPS of ($2.42).

GSA Capital Partners LLP boosted its position in Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL - Free Report) by 275.9% in the 1st quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 541,975 shares of the company's stock after purchasing an additional 397,805 shares during the period. GSA Capital Partners LLP owned approximately 0.75% of Zentalis Pharmaceuticals worth $862,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other institutional investors have also added to or reduced their stakes in the company. Corton Capital Inc. purchased a new position in Zentalis Pharmaceuticals during the fourth quarter valued at approximately $32,000. Captrust Financial Advisors purchased a new position in Zentalis Pharmaceuticals during the fourth quarter valued at approximately $33,000. Prudential Financial Inc. purchased a new position in Zentalis Pharmaceuticals during the fourth quarter valued at approximately $39,000. Cerity Partners LLC purchased a new position in Zentalis Pharmaceuticals during the fourth quarter valued at approximately $40,000. Finally, Vident Advisory LLC purchased a new position in Zentalis Pharmaceuticals during the fourth quarter valued at approximately $45,000.

Zentalis Pharmaceuticals Price Performance

NASDAQ ZNTL traded down $0.04 on Wednesday, hitting $1.38. The stock had a trading volume of 286,754 shares, compared to its average volume of 1,256,465. The business's fifty day moving average price is $1.36 and its 200 day moving average price is $1.57. Zentalis Pharmaceuticals, Inc. has a 52-week low of $1.01 and a 52-week high of $5.44. The stock has a market cap of $98.93 million, a price-to-earnings ratio of -0.44 and a beta of 1.71.

Zentalis Pharmaceuticals (NASDAQ:ZNTL - Get Free Report) last released its quarterly earnings results on Wednesday, May 14th. The company reported ($0.67) earnings per share (EPS) for the quarter, hitting the consensus estimate of ($0.67). As a group, sell-side analysts anticipate that Zentalis Pharmaceuticals, Inc. will post -2.42 EPS for the current year.

Analysts Set New Price Targets

Several brokerages recently issued reports on ZNTL. Wedbush reissued a "neutral" rating and set a $4.00 price objective on shares of Zentalis Pharmaceuticals in a report on Thursday, May 15th. HC Wainwright reissued a "buy" rating and set a $10.00 price objective on shares of Zentalis Pharmaceuticals in a report on Thursday, May 15th. Three equities research analysts have rated the stock with a hold rating and three have given a buy rating to the stock. Based on data from MarketBeat.com, the company has an average rating of "Moderate Buy" and a consensus target price of $8.37.

Zentalis Pharmaceuticals Company Profile

Zentalis Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics for the treatment of various cancers. Its products candidatures include the ZN-c3, an inhibitor of WEE1, a protein tyrosine kinase for the treatment of inhibitor for advanced solid tumors and hematological malignancies; in Phase 2 clinical trial as a monotherapy for the treatment of uterine serous carcinoma indications; Phase 2 clinical trial in Cyclin E1 driven high-grade serous ovarian cancer, fallopian tube, or primary peritoneal cancer; Phase 1/2 clinical trial in combination with PARPi for platinum-resistant ovarian cancer; Phase 1b clinical trial in combination with chemotherapy in platinum-resistant ovarian, and peritoneal or fallopian tube cancer; Phase 1/2 clinical trial in combination with chemotherapy in relapsed or refractory osteosarcoma; Phase 1/2 clinical trial with encorafenib and cetuximab for mutant metastatic colorectal cancer; and Phase 1/2 clinical trial in combination with chemotherapy in pancreatic cancer.